LONG GROVE PHARMS
PharmaLONG GROVE PHARMS is a pharmaceutical company focused on Metabolic, Cardiovascular, Infectious Disease. Key products include NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE.
LONG GROVE PHARMS's Key Drugs
LONG GROVE PHARMS's core commercial portfolio centers on NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, spanning Metabolic and Cardiovascular — its most strategically important drugs approved in the last 15 years.
LONG GROVE PHARMS's Recent FDA Approvals
New NDA/BLA approvals for LONG GROVE PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
LONG GROVE PHARMS's Therapeutic Areas
LONG GROVE PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LONG GROVE PHARMS's Top Competitors
LONG GROVE PHARMS's closest competitors by therapeutic-area and drug-target overlap include Baxter, Merck, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LONG GROVE PHARMS Pipeline Snapshot
Active clinical trials for LONG GROVE PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2008-01-29
- Latest
- 2026-03-17
- Applications
- 12